MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients With Tumors With Aberrations in the FGFR Pathway
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs ABSK 091 (Primary)
- Indications Glioblastoma; Lymphoma; Multiple myeloma; Solid tumours
- Focus Therapeutic Use
- Acronyms MATCH-Subprotocol W
- 08 Jun 2021 Status changed from active, no longer recruiting to completed.
- 26 Jun 2020 New trial record